Physician profile
Daniel J Cole
NPI 1477539062
$489.55
in general payments reported to CMS, 2019-2025
9 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2021: $163 · 2022: $34.13 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $161.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $166.94 | 2021-2025 | Lumenis Pulse 120h |
| Pfizer INC. | $117.08 | 2019 | |
| Janssen Biotech, INC. | $103.12 | 2025 | Rybrevant, Carvykti |
| Janssen Scientific Affairs, LLC | $40.88 | 2025 | Erleada |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Bioventus LLC | $18.11 | 2021 | |
| Coloplast Corp | $13.32 | 2019 | |
| Ambu INC. | $6.17 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$986.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.